Med tech VC HealthQuest aims for $175M new fund
12 January 2016
HealthQuest Capital raised a $110 million med tech fund and spun out of Sofinnova Ventures last year. That kind of commitment is remarkable in a segment long stigmatized as offering poor returns and few exit opportunities. But now the firm has gone even further.
Epic Sciences Receives CAP Accreditation
11 January 2016
Epic Sciences announced today that they have received notice of their accreditation from the College of American Pathologists (CAP) for its San Diego laboratory. The CAP Laboratory Accreditation Program is recognized bythe United States government as being equally or more stringent than the federal inspection program and is designed to specifically ensure the highest standard of care for all laboratory samples.
2015 in Review: What we saw this year in M&A, PE and VC
11 January 2016
As the end of the year arrives, it's time to reflect. And to close out 2015, the PitchBook Editorial team discusses what we saw this year in M&A, private equity and venture capital, while also looking ahead to what may be in store in the year to come.
The biggest news makers and trending stories of 2015
11 January 2016
Despite turbulent capital markets, it was another record year for biopharmaceutical company financings, both public and private. Significant advances were seen in the burgeoning, complex world of biosimilars. And the behemoth China has repositioned itself to be a drug development powerhouse, giving credence to its new status as the second largest pharma market. Even though great scientific strides were also included in BioWorld's top 10 list (CRISPR/Cas9 gene editing technology) and mega deals rocked the sector, what choked its way up to the top of the list of most impactful stories was, undeniably, the drug pricing debate.
Success Rate for Biopharma Companies Rising as FDA Approves Near-Record Number of NMEs
11 January 2016
It was a busy December for the FDA as it gave the green light to five more new molecular entities (NMEs), boosting the number of NMEs and new therapeutic biological products approved by the U.S. agency in 2015 to 45, an almost 10 percent increase over the 41 NMEs that were approved last year.
China continues to fine-tune drug, food safety procedures
11 January 2016
The government of China continues to refine its legal powers to deal with drug safety issues, according to a release from the country's Supreme Court that says investigations will be streamlined to identify administrative cases that potentially involve major criminal breaches.
Clearside Biomedical, Inc. Files Registration Statement for Proposed Initial Public Offering
08 January 2016
Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the eye, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission related to Clearside’s proposed initial public offering of shares of its common stock. The number of shares to be offered and the price range for the proposed offering have not been determined.
Sherer and White to Receive 2016 Georgia Bio Industry Growth Awards
08 January 2016
Todd Sherer, PhD, Associate Vice President & Executive Director of the Emory University Office of Technology Transfer, and Daniel White, President and CEO of Clearside Biomedical Inc. are the recipients of the 2016 Georgia Bio Industry Growth Awards.
FDA accepts application of cenicriviroc for primary sclerosing cholangitis
08 January 2016
Tobira Therapeutics announced that the FDA and Health Canada have accepted its investigational new drug and clinical trial applications for review of cenicriviroc for the treatment of primary sclerosing cholangitis.
Atlas Genetics appoints Bob Johnston as Chief Financial Officer
08 January 2016
Atlas Genetics Ltd (“Atlas Genetics” or the “Company”), the ultra-rapid Point-Of-Care (POC) molecular diagnostics company, today announces the appointment of Bob Johnston as Chief Financial Officer, who will be based in the recently opened Boston office.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
The overall mortality rate of the population in Russia decreased by 7% in 2023
28 March 2024
Russia to collaborate with Hungary and Serbia in nuclear medicine
28 March 2024
Researchers propose novel test for pyrogen detection
27 March 2024
Parkinson’s infusion treatment demonstrates advantage over oral delivery
27 March 2024